A head-to-head evaluation of two distinct AI approaches to protein engineering: Salesforce's generative language model versus Meta's structure-first predictor.
Comparison
Salesforce's ProGen vs. Meta's ESMFold
A technical comparison of two leading AI models for protein engineering. ProGen excels at de novo sequence generation, while ESMFold specializes in high-accuracy structure prediction from sequence. This guide helps CTOs and research leads choose the right tool for their drug discovery pipeline.
THE ANALYSIS
Introduction
Salesforce's ProGen excels at generating novel, functional protein sequences by treating protein design as a language modeling problem. Trained on over 280 million protein sequences, it learns the statistical 'grammar' of amino acids to produce viable designs. For example, in a landmark study, researchers used ProGen to create functional enzymes not found in nature, with experimentally validated activity. Its strength lies in massive-scale de novo generation, enabling the rapid exploration of a vast sequence space for novel therapeutic or industrial proteins, a process central to platforms focused on early discovery compression.
Meta's ESMFold takes a fundamentally different approach by prioritizing accurate and ultra-fast protein structure prediction from a single sequence. Built upon the ESM-2 language model, it can predict a protein's 3D fold in seconds, a task that previously took hours or days. This results in a critical trade-off: while ESMFold is unparalleled for structure-based analysis and validation, its generative capabilities are more constrained compared to ProGen's. It is exceptionally powerful for tasks like understanding variant effects or guiding designs where structural integrity is the primary constraint, a key function in building digital twin technologies for oncology.
The key trade-off hinges on your primary objective in the drug discovery pipeline. If your priority is high-throughput ideation of novel protein sequences with desired functions, choose ProGen. It is the engine for generative exploration. If you prioritize rapid, accurate structural validation and analysis of existing or designed sequences to assess stability and binding, choose ESMFold. It acts as the essential quality control and insight layer. For a comprehensive platform, the most effective strategy often involves a hybrid workflow, using ProGen for generation and ESMFold for downstream structural evaluation, a pattern seen in leading AI-native platforms in 2026.
HEAD-TO-HEAD COMPARISON
ProGen vs. ESMFold: Feature Comparison
Direct comparison of Salesforce's generative protein language model and Meta's structure prediction model for AI-driven drug discovery.
| Metric | Salesforce ProGen | Meta ESMFold |
|---|---|---|
Primary Function | De novo protein sequence generation | Protein structure prediction from sequence |
Core Architecture | Transformer-based language model (GPT-style) | ESM-2 protein language model with folding head |
Structure Prediction Speed | < 1 second per protein | |
Training Data Scale | ~280 million protein sequences | ~65 million protein sequences (UniRef) |
Typical Output | Novel, functional protein sequences | 3D atomic coordinates (PDB format) |
Design Workflow Integration | Generative first step for novel candidates | Validation/analysis step for designed sequences |
Open-Source Availability | ||
Reported Accuracy (CASP15) | ~87% GDT_TS (top model) |
ProGen vs. ESMFold
TL;DR Summary
Key strengths and trade-offs at a glance for generative protein design in 2026.
01
Choose ProGen for De Novo Sequence Generation
Specific advantage: Trained on 280 million protein sequences, enabling high-throughput generation of novel, diverse protein sequences with specified functions. This matters for scaffold design and functional motif insertion where exploring a vast sequence space is critical.
02
Choose ESMFold for Rapid, Accurate Structure Prediction
Specific advantage: Predicts 3D protein structure from a single sequence in seconds, with accuracy competitive with AlphaFold2 but at ~60x the speed. This matters for iterative design cycles and validating generated sequences where fast structural feedback is essential.
03
ProGen's Strength: Conditioning on Properties
Specific advantage: Can be conditioned on metadata like organism, function, or stability, allowing for directed generation toward desired traits. This matters for thermostability engineering or humanization of therapeutic proteins where specific property optimization is the goal.
04
ESMFold's Strength: End-to-End Single Model
Specific advantage: Uses a single transformer model for end-to-end structure prediction, avoiding the complex multiple sequence alignment (MSA) step. This matters for orphan proteins or novel scaffolds with few homologs, where traditional MSA-based methods struggle.
CHOOSE YOUR PRIORITY
User Scenarios: When to Choose Which
Salesforce's ProGen for De Novo Design
Verdict: The clear choice for sequence-first generation. ProGen excels at generating novel, functional protein sequences from scratch. Its core strength lies in its language model architecture, trained on massive protein sequence databases, which allows it to propose sequences with high predicted fitness for a desired function or property. This makes it ideal for projects where you need to explore a vast, unexplored sequence space, such as designing enzymes with new catalytic activities or generating thermostable protein scaffolds. Its generative approach is faster and more scalable than structure-first methods when the primary constraint is a functional specification.
Meta's ESMFold for De Novo Design
Verdict: Best when 3D structure is the non-negotiable starting point. While ESMFold can be used for design, its primary superpower is ultra-fast, accurate structure prediction from a single sequence. For de novo design, it shines in an inverse folding or protein hallucination workflow. Here, you start with a desired 3D structure or structural motif (e.g., a specific binding pocket), and ESMFold helps generate sequences that are predicted to fold into that shape. Choose ESMFold when your design goal is structurally defined—like creating a binder to fit a specific antigen cleft—and you need rapid, iterative validation of your sequence proposals against the target fold.
THE ANALYSIS
Verdict and Final Recommendation
A decisive comparison of two distinct AI approaches for protein engineering, helping you select the right tool for your discovery pipeline.
Salesforce's ProGen excels at generating novel, functional protein sequences with high designability because it is a language model trained on a massive corpus of protein sequences and their associated properties. This enables it to perform conditional generation, creating sequences optimized for specific functions or structural motifs. For example, ProGen has been used to design enzymes with novel catalytic activity not found in nature, demonstrating its power for de novo protein creation where the goal is to explore a vast sequence space for a desired function.
Meta's ESMFold takes a different approach by leveraging a protein language model trained on evolutionary-scale data to predict 3D structure directly from a single sequence. This results in a powerful structure-first paradigm. While it can be used for design, its core strength is rapid and accurate structure prediction, achieving atomic-level accuracy (Cα RMSD) competitive with AlphaFold2 but at speeds up to 60 times faster. This makes it ideal for high-throughput analysis and validating the structural plausibility of generated sequences.
The key trade-off is between generative breadth and predictive precision. If your priority is exploring novel sequence space for de novo design or functional optimization, choose ProGen. Its language model architecture is purpose-built for generation, making it the superior tool for inventing new proteins. If you prioritize rapid, accurate structural validation, folding analysis, or structure-guided design, choose ESMFold. Its speed and accuracy provide an essential reality check for any generative pipeline, ensuring designs are physically plausible. For a robust platform, consider integrating both: using ProGen for generation and ESMFold for rapid in-silico validation, a pattern discussed in our guide on AI-native platforms for drug discovery.
Contact
Talk to the team about your AI system.
Share what you are building, where you need help, and what needs to ship next. We will reply with the right next step.
01
NDA available
We can start under NDA when the work requires it.
02
Direct team access
You speak directly with the team doing the technical work.
03
Clear next step
We reply with a practical recommendation on scope, implementation, or rollout.
30m
working session
Direct
team access